{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:27:40Z","timestamp":1789687660188,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-025-00744-6","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T17:37:00Z","timestamp":1746293820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of dolutegravir-based treatment among HIV\/AIDS patients in Nkembo Outpatient Treatment Center, Gabon"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8367-5497","authenticated-orcid":false,"given":"Christian","family":"Mangala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Moukanda-Ifoundou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Maulot-Bangola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Moutsinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mombo-Maganga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge Christian","family":"Okolongo-Mayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Ongali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy Joseph","family":"Lemamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachyda","family":"Massolou-Outata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"key":"744_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ijid.2021.08.057","volume":"112","author":"B Kikaire","year":"2021","unstructured":"Kikaire B, Ssemanda M, Asiimwe A, et al. HIV viral load suppression following intensive adherence counseling among people living with HIV on treatment at military-managed health facilities in Uganda. Int J Infect Dis. 2021;112:45\u201351. https:\/\/doi.org\/10.1016\/j.ijid.2021.08.057. [Crossref] [Goole scholar] [PubMed].","journal-title":"Int J Infect Dis [Internet]"},{"key":"744_CR2","unstructured":"World Health Organization.HIV. and AIDS. Available on https:\/\/www.who.int\/fr\/news-room\/fact-sheets\/detail\/hivaids?gad_source=1&gclid=CjwKCAjwjeuyBhBuEiwAJ3vuoUBH7h48s1NtESenMoV1D3zUM7k3F5on_rXENM57CtgLQl3I2F1aSBoCjdcQAvD_BwE"},{"issue":"12","key":"744_CR3","doi-asserted-by":"publisher","first-page":"e809","DOI":"10.1016\/s2352-3018(19)30230-9","volume":"6","author":"A Pandey","year":"2019","unstructured":"Pandey A, Galvani AP. Le Fardeau mondial du VIH et les perspectives de contr\u00f4le. Lancet VIH. 2019;6(12):e809\u201311. https:\/\/doi.org\/10.1016\/s2352-3018(19)30230-9. [Crossref] [Goole scholar] [PubMed].","journal-title":"Lancet VIH [Internet]"},{"issue":"8","key":"744_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3390\/tropicalmed8080391","volume":"8","author":"A Gemechu","year":"2023","unstructured":"Gemechu A, Mihret A, Atire FA, et al. Virological Non-Suppression among newly diagnosed HIV-Positive individuals on Dolutegravir-Based antiretroviral treatment in Eastern Ethiopia: Follow-Up study. Trop Med Infect Disease. 2023;8(8):391. https:\/\/doi.org\/10.3390\/tropicalmed8080391. [Crossref] [Goole scholar] [PubMed].","journal-title":"Trop Med Infect Disease [Internet]"},{"key":"744_CR5","doi-asserted-by":"publisher","unstructured":"Gebremedhin T, Aynalem M, Adem M et al. Dolutegravir based therapy showed CD4\u2009+\u2009T cell count recovery and viral load suppression among ART na\u00efve people living with HIV AIDS: a pilot evaluation. Scientific Reports. 2024;14(1). Available from: https:\/\/doi.org\/10.1038\/s41598-024-53282-y [Crossref] [Goole scholar] [PubMed].","DOI":"10.1038\/s41598-024-53282-y"},{"issue":"8","key":"744_CR6","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3390\/v15081683","volume":"15","author":"J Fokam","year":"2023","unstructured":"Fokam J, Chenwi CA, Takou D, et al. Laboratory based surveillance of HIV-1 acquired drug resistance in Cameroon: implications for use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line regimens. Viruses. 2023;15(8):1683. https:\/\/doi.org\/10.3390\/v15081683. [Crossref] [Goole scholar] [PubMed].","journal-title":"Viruses [Internet]"},{"key":"744_CR7","doi-asserted-by":"publisher","unstructured":"Kemper KE, Augusto O, Gloyd S et al. HIV viral load testing and monitoring in C\u00f4te d\u2019Ivoire: A survival analysis of viral load testing and suppression, and evaluation of adherence to national recommendations. Duvvuri VR, editor. PLOS Global Public Health. 2023;3(9):e0001822. https:\/\/doi.org\/10.1371\/journal.pgph.0001822 [Crossref] [Goole scholar] [PubMed].","DOI":"10.1371\/journal.pgph.0001822"},{"key":"744_CR8","unstructured":"The DHS Proram. Third Demographic and Health Survey in Gabon. Available on https:\/\/dhsprogram.com\/pubs\/pdf\/PR137\/PR137.pdf"},{"issue":"4","key":"744_CR9","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/jac\/dkaa537","volume":"76","author":"JD Engone-Ondo","year":"2020","unstructured":"Engone-Ondo JD, Mouinga-Ond\u00e9m\u00e9 A, L\u00e9kana-Douki SE, et al. High rate of virological failure and HIV drug resistance in semi-rural Gabon and implications for dolutegravir-based regimen efficacy. J Antimicrob Chemother. 2020;76(4):1051\u20136. https:\/\/doi.org\/10.1093\/jac\/dkaa537. [Crossref] [Goole scholar] [PubMed].","journal-title":"J Antimicrob Chemother [Internet]"},{"key":"744_CR10","doi-asserted-by":"publisher","unstructured":"Karabay O. Concerns and clarifications regarding the Article 'Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first line ART regimen in Zimbabwe.\u2019 AIDS. 2024; 38(8):1273. https:\/\/doi.org\/10.1097\/qad.0000000000003885 [Crossref] [Goole scholar] [PubMed].","DOI":"10.1097\/qad.0000000000003885"},{"key":"744_CR11","doi-asserted-by":"publisher","first-page":"104552","DOI":"10.1016\/j.antiviral.2019.104552","volume":"169","author":"B Rossetti","year":"2019","unstructured":"Rossetti B, Baldin G, Sterrantino G, et al. Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected Na\u00efve patients: results from a multicenter cohort study. Antiviral Res. 2019;169:104552. https:\/\/doi.org\/10.1016\/j.antiviral.2019.104552. [Crossref] [Goole scholar] [PubMed].","journal-title":"Antiviral Res [Internet]"},{"issue":"3","key":"744_CR12","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.cell.2015.01.020","volume":"160","author":"LB Cohn","year":"2015","unstructured":"Cohn LB, Silva IT, Oliveira TY, et al. HIV-1 integration landscape during latent and active infection. Cell. 2015;160(3):420\u201332. https:\/\/doi.org\/10.1016\/j.cell.2015.01.020. [Crossref] [Goole scholar] [PubMed].","journal-title":"Cell [Internet]"},{"key":"744_CR13","doi-asserted-by":"publisher","DOI":"10.3410\/f.725332612.793541813","author":"S Crowe","year":"2018","unstructured":"Crowe S. Faculty Opinions recommendation of HIV-1 integration landscape during latent and active infection. Faculty Opinions \u2013 Post-Publication Peer Review of the Biomedical Literature. H1 Connect; 2018. https:\/\/doi.org\/10.3410\/f.725332612.793541813 [Crossref] [Goole scholar] [PubMed]."},{"issue":"8","key":"744_CR14","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1097\/qad.0000000000002533","volume":"34","author":"R Nasreddine","year":"2020","unstructured":"Nasreddine R, Florence E, Vandercam B, et al. Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients. AIDS. 2020;34(8):1151\u20139. https:\/\/doi.org\/10.1097\/qad.0000000000002533. [Crossref] [Goole scholar] [PubMed].","journal-title":"AIDS [Internet]"},{"key":"744_CR15","doi-asserted-by":"publisher","unstructured":"Seyed-Alinaghi S, Afsahi AM, Moradi A, et al. Current ART, determinants for virologic failure and implications for HIV drug resistance: an umbrella review. AIDS Res Therapy. 2023;20(1). https:\/\/doi.org\/10.1186\/s12981-023-00572-6. [Crossref] [Goole scholar] [PubMed].","DOI":"10.1186\/s12981-023-00572-6"},{"key":"744_CR16","doi-asserted-by":"publisher","unstructured":"Bvochora T, Satyanarayana S, Takarinda KC et al. Enhanced adherence counselling and viral load suppression in HIV seropositive patients with an initial high viral load in Harare, Zimbabwe: Operational issues. Mor O, editor. Plos one. 2019;14(2):e0211326. https:\/\/doi.org\/10.1371\/journal.pone.0211326 T [Crossref] [Goole scholar] [PubMed].","DOI":"10.1371\/journal.pone.0211326"},{"key":"744_CR17","doi-asserted-by":"publisher","unstructured":"Ochodo EA, Olwanda EE, Deeks JJ, Mallett S. Point-of-care viral load tests to detect high HIV viral load in people living with HIV\/AIDS attending health facilities. Cochrane Database Syst Reviews. 2022;2022(3). https:\/\/doi.org\/10.1002\/14651858.cd013208.pub2. [Crossref] [Goole scholar] [PubMed].","DOI":"10.1002\/14651858.cd013208.pub2"},{"issue":"9","key":"744_CR18","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1056\/nejmoa1904340","volume":"381","author":"The NAMSAL ANRS 12313 Study Group","year":"2019","unstructured":"The NAMSAL ANRS 12313 Study Group. Dolutegravir-Based or Low-Dose Efavirenz\u2013Based regimen for the treatment of HIV-1. New Engl J Med. 2019;381(9):816\u201326. https:\/\/doi.org\/10.1056\/nejmoa1904340. [Crossref] [Goole scholar] [PubMed].","journal-title":"New Engl J Med [Internet]"},{"key":"744_CR19","doi-asserted-by":"publisher","unstructured":"Mehari EA, Muche EA, Gonete KA et al. Treatment satisfaction and its associated factors of dolutegravir based Regimen in a Resource limited setting. Patient preference and adherence. 2021 15:1177\u201385https:\/\/doi.org\/10.2147\/ppa.s308571 [Crossref] [Goole scholar] [PubMed].","DOI":"10.2147\/ppa.s308571"},{"key":"744_CR20","doi-asserted-by":"publisher","unstructured":"Desta AA, Woldearegay TW, Futwi N, et al. HIV virological non-suppression and factors associated with non-suppression among adolescents and adults on antiretroviral therapy in Northern Ethiopia: a retrospective study. BMC Infect Dis. 2020;20(1). https:\/\/doi.org\/10.1186\/s12879-019-4732-6. [Crossref] [Goole scholar] [PubMed].","DOI":"10.1186\/s12879-019-4732-6"},{"key":"744_CR21","doi-asserted-by":"publisher","unstructured":"Kabiibi F, Tamukong R, Muyindike W et al. Virological Non-Suppression, Non-Adherence and the associated factors among people living with HIV on Dolutegravir-Based Regimens: A Retrospective cohort study. HIV\/AIDS - Research and palliative care.2024; 16:95\u2013107. https:\/\/doi.org\/10.2147\/hiv.s449947 [Crossref] [Goole scholar] [PubMed].","DOI":"10.2147\/hiv.s449947"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00744-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00744-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00744-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T17:37:05Z","timestamp":1746293825000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00744-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00744-6","relation":{"references":[{"id-type":"doi","id":"10.3410\/f.725332612.793541813","asserted-by":"subject"}]},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,3]]},"assertion":[{"value":"24 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the management of the Outpatient Treatment Center, which also chairs the Institutional Ethics Committee. Number: 00242 DOTC\/IEC. Informed consent and written was obtained from each study participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}